A recombinant botulinum toxin type A called YY001 recently completed a Phase III trial showing favorable efficacy and safety results compared to onabotulinumtoxinA for glabellar lines. While the product is not available in the United States, understanding how recombinant toxins differ from traditional formulations helps aesthetic providers evaluate emerging data and marketing claims.

Patients are already asking about the salmon facial. Here’s what the clinical evidence shows, why the U.S. entry point is lower than most providers expect, and how to evaluate it as a revenue opportunity for your practice.

Relfydess (relabotulinumtoxinA) is a ready-to-use, complex-free liquid neurotoxin with Phase 3 data supporting rapid onset and sustained improvement for glabellar lines and crow’s feet in many patients. Here’s what aesthetic providers need to know about its clinical profile—and how to prepare their practice before adding it to the menu.